Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Jones Lang LaSalle Inc (JLL) vs Revvity Inc (RVTY) Price & Performance

Jones Lang LaSalle IncTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

Jones Lang LaSalle Inc vs Revvity Inc — how do they compare? Jones Lang LaSalle Inc trades at $327.5 (market cap $15.12B), while Revvity Inc trades at $109.79 (market cap $11.87B). The key difference: Jones Lang LaSalle Inc is the larger of the two by market cap, and Revvity Inc pays a 0.26% dividend while Jones Lang LaSalle Inc pays none. Which is the better fit depends on your goals.

JLLRVTY
Market Cap
$15.12B$11.87B
Sector
Real EstateTechnology
52-Week High
$358.66$117.75
52-Week Low
$253.48$82.26
Enterprise Value
$18.66B$14.36B
Dividend Yield
0.26%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Jones Lang LaSalle Inc

JLL trades at $325.94, down 1.43% today, but maintains a bullish technical outlook with strong moving average signals. The company shows solid fundamental improvement with revenue growing from $20.9B in 2022 to $26.1B in 2025, while net income margin expanded to 3.35%. Recent earnings beats and positive analyst coverage (54.55% buy rating) support the stock's upward trajectory, with a consensus price target of $405.50 representing 24.4% upside potential.

JLL presents a compelling investment case with improving profitability, strong cash flow generation ($1.19B operating cash flow in 2025), and positive business momentum in commercial real estate services. Key risks include exposure to commercial real estate cycles and potential economic slowdowns, but the company's debt-to-asset ratio improvement to 9.32% and consistent earnings beats provide fundamental support for continued growth.

Revvity Inc

RVTY trades at $106.44, down 3.37% today, but maintains a bullish technical outlook with strong analyst support. The company has consistently beaten earnings estimates for three consecutive quarters, with Q2 2026 results expected on August 4, 2026. Recent developments include AI integration partnerships and FDA clearances, supporting growth in its diagnostics and life sciences segments. Valuation metrics show a P/E of 52.96 and P/S of 4.35, reflecting premium pricing for its growth prospects.

The stock presents a balanced opportunity with analyst consensus pointing to 4.7% upside to the $111.43 price target. Strong institutional ownership and zero sell ratings indicate confidence, though high valuation multiples and negative cash flow trends pose risks. Earnings momentum from recent beats and strategic AI expansions provide catalysts, but investors should monitor margin pressures and China market exposure highlighted in recent quarters.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Jones Lang LaSalle Inc

Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.

Read more on JLL

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY